What the FDA labels say about taking them together
Eluxadoline and rosuvastatin
Eluxadoline's FDA label of July 16, 2024 names rosuvastatin in its drug interactions section; the rosuvastatin labels PlainMeds reads (2) do not name eluxadoline. The eluxadoline label: “VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rhabdomyolysis [ see …”
Check it at the source: the eluxadoline FDA label on DailyMed (effective July 16, 2024, Allergan, Inc.); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the eluxadoline label say about rosuvastatin?
Eluxadoline label, drug interactionsClinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rhabdomyolysis [ see Clinical Pharmacology ( 12.3 ) ] Intervention: Use the lowest effective dose of rosuvastatin (see prescribing information of rosuvastatin for additional information on recommended dosing). See full prescribing information for clinically relevant interactions.
Source: FDA drug label (Viberzi), NDA206940 (Abbvie), as published by Allergan, Inc., effective July 16, 2024 (SPL set 7821bd40-4c84-4984-951b-6436ae20421a), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about eluxadoline?
Rosuvastatin's label (effective September 4, 2026) and its 1 other brand-application label do not name eluxadoline in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Eluxadoline | Rosuvastatin | |
|---|---|---|
| Labeled for | Irritable bowel syndrome, Diarrhea | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $28.09 per tablet 100 mg tablet | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once